Juan Manuel Vásquez-Jiménez
Research Subjects
Juan Manuel Vásquez-Jiménez has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Luisana Molina Pimienta
Clínica Universitaria Colombia , Keralty Group , Bogotá , Colombia
3 shared publications - Sandra Brigitte Amado Garzon
Hospital Universitario San Ignacio
2 shared publications Alejandra Cañas-Arboleda
Department of Internal Medicine, Hospital Universitario San Ignacio, Bogotá, Colombia
1 shared publication- Andrés Felipe Bejarano-Ramirez
Fundación Santa Fe de Bogota
1 shared publication - Camilo Rueda-Ortiz
School of Medicine and Health Sciences , Universidad Del Rosario , Bogotá , Colombia , urosario.edu.co
1 shared publication - Carlos Eduardo Bonilla
Centro de Investigación y Tratamiento sobre Cáncer Luis Carlos Sarmiento Angulo (CTIC), Bogotá, Colombia
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Journal of Skin Cancer
- Vol. 2026 (1) , 3904810
Real‐World Outcomes of Immune Checkpoint Inhibitors in Melanoma, Including Acral and Mucosal Subtypes: A Retrospective Cohort Study From a Latin American Center
Background: Real‐world evidence on immune checkpoint inhibitors (ICIs) in Latin American patients with melanoma remains limited, particularly for acral and mucosal subtypes. We evaluated survival, radiologic response, immune‐related adverse events (irAEs), and exploratory factors associated with outcomes in a Colombian cohort. Methods: This single‐center retrospective cohort included consecutive patients with histologically confirmed melanoma who received ≥ 1 ICI dose between February 2017 and November 2022. Patients were classified as adjuvant‐ or palliative‐intent. rwOS and irAEs were assessed in the overall cohort; rwDFS in the adjuvant‐intent cohort; and rwPFS and best radiologic response in the palliative‐intent cohort. Survival was estimated using Kaplan–Meier methods, with median follow‐up calculated by reverse Kaplan–Meier. Primary Cox proportional hazards analyses of rwPFS and rwOS were restricted to the palliative‐intent cohort. Results: Fifty‐seven patients were included: 20 received adjuvant‐ and 37 palliative‐intent therapy. Median age was 65 years (IQR, 54–76); acral and mucosal melanoma accounted for 26 (45.6%) and 11 (19.3%) cases, respectively. Median follow‐up was 32.3 months (95% CI, 25.9–42.3). In the adjuvant‐intent cohort, median rwDFS and rwOS were 23.3 months (95% CI, 4.8–not reached) and 33.0 months (95% CI, 30.1–not reached), respectively. In the palliative‐intent cohort, median rwPFS and rwOS were 8.5 months (95% CI, 6.0–24.1) and 26.0 months (95% CI, 17.9–not reached), respectively. Among 31 response‐evaluable patients, ORR was 38.7% (95% CI, 23.7–56.2) and DCR was 54.8% (95% CI, 37.8–70.8). IrAEs were documented in 31 patients (54.4%); five had Grade 3 events, and no Grade 4 or five irAEs were documented. In adjusted models, ECOG performance status and melanoma subtype were not significantly associated with rwPFS or rwOS. Conclusions: ICIs demonstrated antitumor activity in this Colombian real‐world cohort, including patients with acral and mucosal melanoma, although survival estimates were numerically lower than those reported in selected pivotal trials. Documented toxicity was predominantly low grade. Exploratory analyses suggested more favorable outcomes in patients with conventional cutaneous melanoma.
- 1 January 2026
- Published by Wiley in Journal of Skin Cancer
- Vol. 2026 (1) , 3904810
Open AccessReal‐World Outcomes of Immune Checkpoint Inhibitors in Melanoma, Including Acral and Mucosal Subtypes: A Retrospective Cohort Study From a Latin American Center
Background: Real‐world evidence on immune checkpoint inhibitors (ICIs) in Latin American patients with melanoma remains limited, particularly for acral and mucosal subtypes. We evaluated survival, radiologic response, immune‐related adverse events (irAEs), and exploratory factors associated with outcomes in a Colombian cohort. Methods: This single‐center retrospective cohort included consecutive patients with histologically confirmed melanoma who received ≥ 1 ICI dose between February 2017 and November 2022. Patients were classified as adjuvant‐ or palliative‐intent. rwOS and irAEs were assessed in the overall cohort; rwDFS in the adjuvant‐intent cohort; and rwPFS and best radiologic response in the palliative‐intent cohort. Survival was estimated using Kaplan–Meier methods, with median follow‐up calculated by reverse Kaplan–Meier. Primary Cox proportional hazards analyses of rwPFS and rwOS were restricted to the palliative‐intent cohort. Results: Fifty‐seven patients were included: 20 received adjuvant‐ and 37 palliative‐intent therapy. Median age was 65 years (IQR, 54–76); acral and mucosal melanoma accounted for 26 (45.6%) and 11 (19.3%) cases, respectively. Median follow‐up was 32.3 months (95% CI, 25.9–42.3). In the adjuvant‐intent cohort, median rwDFS and rwOS were 23.3 months (95% CI, 4.8–not reached) and 33.0 months (95% CI, 30.1–not reached), respectively. In the palliative‐intent cohort, median rwPFS and rwOS were 8.5 months (95% CI, 6.0–24.1) and 26.0 months (95% CI, 17.9–not reached), respectively. Among 31 response‐evaluable patients, ORR was 38.7% (95% CI, 23.7–56.2) and DCR was 54.8% (95% CI, 37.8–70.8). IrAEs were documented in 31 patients (54.4%); five had Grade 3 events, and no Grade 4 or five irAEs were documented. In adjusted models, ECOG performance status and melanoma subtype were not significantly associated with rwPFS or rwOS. Conclusions: ICIs demonstrated antitumor activity in this Colombian real‐world cohort, including patients with acral and mucosal melanoma, although survival estimates were numerically lower than those reported in selected pivotal trials. Documented toxicity was predominantly low grade. Exploratory analyses suggested more favorable outcomes in patients with conventional cutaneous melanoma.
- Open Access
- 5 December 2024
- Published by Asociacion Colombiana de Hematologia y Oncologia in Revista Colombiana de Hematología y Oncología
- Vol. 11 (2) , 103-112
Respuesta profunda y duradera en cáncer de pulmón con mutación L718Q en EGFR, adquirida después de la terapia con osimertinib
Actionable mutations in the epidermal growth factor receptor (EGFR) gene are prevalent in non-small cell lung cancer (NSCLC). The advent of targeted therapy using tyrosine kinase inhibitors (TKIs) has significantly improved patient outcomes. However, the eventual development of resistance poses a substantial challenge. Molecular profiling is essential for tailoring personalized treatment strategies. Case Description: A 61-year-old female patient with NSCLC harboring the L858R mutation in EGFR was initially treated with osimertinib, achieving a complete response. Nevertheless, at 26 months, the disease progressed with the emergence of the L718Q mutation in EGFR. Osimertinib was discontinued, and a regimen of chemoimmunotherapy combined with erlotinib was initiated. The patient achieved a second complete response and remained progression-free for 14 months. Discussion: The L718Q mutation is rare and confers resistance to osimertinib. However, as demonstrated in this case, the mutation may render the tumor susceptible to alternative treatments. Several case reports suggest modest efficacy with various drug combinations, including other TKIs, chemotherapy, and antiangiogenic agents. This case represents one of the longest progression-free survival periods reported in this context. This underscores the importance of re-evaluating molecular targets upon disease progression in EGFR-mutated non-small cell lung cancer (NSCLC).
- 5 December 2024
- Published by Asociacion Colombiana de Hematologia y Oncologia in Revista Colombiana de Hematología y Oncología
- Vol. 11 (2) , 103-112
Open AccessRespuesta profunda y duradera en cáncer de pulmón con mutación L718Q en EGFR, adquirida después de la terapia con osimertinib
Actionable mutations in the epidermal growth factor receptor (EGFR) gene are prevalent in non-small cell lung cancer (NSCLC). The advent of targeted therapy using tyrosine kinase inhibitors (TKIs) has significantly improved patient outcomes. However, the eventual development of resistance poses a substantial challenge. Molecular profiling is essential for tailoring personalized treatment strategies. Case Description: A 61-year-old female patient with NSCLC harboring the L858R mutation in EGFR was initially treated with osimertinib, achieving a complete response. Nevertheless, at 26 months, the disease progressed with the emergence of the L718Q mutation in EGFR. Osimertinib was discontinued, and a regimen of chemoimmunotherapy combined with erlotinib was initiated. The patient achieved a second complete response and remained progression-free for 14 months. Discussion: The L718Q mutation is rare and confers resistance to osimertinib. However, as demonstrated in this case, the mutation may render the tumor susceptible to alternative treatments. Several case reports suggest modest efficacy with various drug combinations, including other TKIs, chemotherapy, and antiangiogenic agents. This case represents one of the longest progression-free survival periods reported in this context. This underscores the importance of re-evaluating molecular targets upon disease progression in EGFR-mutated non-small cell lung cancer (NSCLC).
- Open Access
- 30 June 2024
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 18 (06) , 880-886
Fever of unknown origin: A 12-year case series in Colombia
Background: Fever of unknown origin (FUO) is a diagnostic challenge with highly heterogeneous causes. Its etiology can change according to the studied regions, and the chance of reaching a diagnosis depends on available resources. The aim of this study is to describe the clinical characteristics, etiology and the usefulness of diagnostic aids in cases of FUO managed over 12 years in a Colombian reference center. Methodology: Single-institution retrospective case series. All cases of FUO between 2006 and 2017 were identified with the help of an electronic medical record search software. Cases of adults with fever for more than three weeks who remained undiagnosed after three days of hospitalization are described. Results: Of 1,009 cases evaluated, 112 cases met the inclusion criteria (median age 43 years, 66% men). The etiologies identified were infectious (31.2%), inflammatory (20.5%), neoplastic (14.3%), and miscellaneous (2.7%) diseases. 31.2% remained without etiological diagnosis. The most frequent conditions were tuberculosis (17%), Hodgkin's lymphoma (7.1%), systemic lupus erythematosus (6.3%), disseminated histoplasmosis, and adult Still's disease. Contrast tomography and biopsies were the studies that most frequently supported or confirmed the final diagnosis. Conclusions: This series of contemporary Latin American cases suggests that the categories of FUO etiologies are similar to those reported in studies from developed countries, with tuberculosis being the most frequent cause in our setting. Our results highlight the importance of tomography-guided invasive studies in the diagnostic approach to FUO.
- 30 June 2024
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 18 (06) , 880-886
Open AccessFever of unknown origin: A 12-year case series in Colombia
Background: Fever of unknown origin (FUO) is a diagnostic challenge with highly heterogeneous causes. Its etiology can change according to the studied regions, and the chance of reaching a diagnosis depends on available resources. The aim of this study is to describe the clinical characteristics, etiology and the usefulness of diagnostic aids in cases of FUO managed over 12 years in a Colombian reference center. Methodology: Single-institution retrospective case series. All cases of FUO between 2006 and 2017 were identified with the help of an electronic medical record search software. Cases of adults with fever for more than three weeks who remained undiagnosed after three days of hospitalization are described. Results: Of 1,009 cases evaluated, 112 cases met the inclusion criteria (median age 43 years, 66% men). The etiologies identified were infectious (31.2%), inflammatory (20.5%), neoplastic (14.3%), and miscellaneous (2.7%) diseases. 31.2% remained without etiological diagnosis. The most frequent conditions were tuberculosis (17%), Hodgkin's lymphoma (7.1%), systemic lupus erythematosus (6.3%), disseminated histoplasmosis, and adult Still's disease. Contrast tomography and biopsies were the studies that most frequently supported or confirmed the final diagnosis. Conclusions: This series of contemporary Latin American cases suggests that the categories of FUO etiologies are similar to those reported in studies from developed countries, with tuberculosis being the most frequent cause in our setting. Our results highlight the importance of tomography-guided invasive studies in the diagnostic approach to FUO.
- Open Access
- 1 January 2024
- Published by SAGE Publications in Sage Open Medicine
- Vol. 12
Factors influencing in-hospital mortality in cancer patients with COVID-19: A retrospective survival analysis
Objective: The aim of this study was to evaluate survival in patients with COVID-19 and cancer, and to find factors associated with early mortality. Methods: Retrospective cohort derived from a registry of a referral center in Bogotá. Survival was analyzed according to the type of neoplasm using Kaplan–Meier method. A cox regression was performed to look for factors associated to higher risk of death. Results: Two hundred fifty-four patients were included with cancer and COVID-19, most of whom were women (median age 68 years; range 19–97). Cardiovascular comorbidities were frequent. Patients with hematologic neoplasms had higher survival than those with solid neoplasms (log-rank test, p = 0.024). C-reactive protein levels (hazard ratio 1.02; 95% confidence interval 1.00–1.03, p = 0.025), Charlson’s comorbidity index (hazard ratio 1.15; 95% confidence interval 1.06–1.26, p = 0.004) and respiratory failure (hazard ratio 4.83; 95% confidence interval 2.47–9.44, p = <0.001) were significantly associated with higher mortality. No interaction between active anticancer therapy and mortality was observed. Conclusion: In contrast to other reports, survival was worse in patients with solid tumors than in those with hematologic neoplasms. Increased C-reactive protein, Charlson’s comorbidity index and respiratory failure were associated with higher in-hospital mortality. This study reveals the complex impact of cancer and its treatment on COVID-19 outcomes, highlighting the persistent risks to cancer patients. It emphasizes monitoring C-reactive protein levels, comorbidities, and respiratory failure as key indicators of poor prognosis. Furthermore, we provide new insights into the differential impact of COVID-19 on cancer patients with solid organ versus hematologic neoplasms.
- 1 January 2024
- Published by SAGE Publications in Sage Open Medicine
- Vol. 12
Open AccessFactors influencing in-hospital mortality in cancer patients with COVID-19: A retrospective survival analysis
Objective: The aim of this study was to evaluate survival in patients with COVID-19 and cancer, and to find factors associated with early mortality. Methods: Retrospective cohort derived from a registry of a referral center in Bogotá. Survival was analyzed according to the type of neoplasm using Kaplan–Meier method. A cox regression was performed to look for factors associated to higher risk of death. Results: Two hundred fifty-four patients were included with cancer and COVID-19, most of whom were women (median age 68 years; range 19–97). Cardiovascular comorbidities were frequent. Patients with hematologic neoplasms had higher survival than those with solid neoplasms (log-rank test, p = 0.024). C-reactive protein levels (hazard ratio 1.02; 95% confidence interval 1.00–1.03, p = 0.025), Charlson’s comorbidity index (hazard ratio 1.15; 95% confidence interval 1.06–1.26, p = 0.004) and respiratory failure (hazard ratio 4.83; 95% confidence interval 2.47–9.44, p = <0.001) were significantly associated with higher mortality. No interaction between active anticancer therapy and mortality was observed. Conclusion: In contrast to other reports, survival was worse in patients with solid tumors than in those with hematologic neoplasms. Increased C-reactive protein, Charlson’s comorbidity index and respiratory failure were associated with higher in-hospital mortality. This study reveals the complex impact of cancer and its treatment on COVID-19 outcomes, highlighting the persistent risks to cancer patients. It emphasizes monitoring C-reactive protein levels, comorbidities, and respiratory failure as key indicators of poor prognosis. Furthermore, we provide new insights into the differential impact of COVID-19 on cancer patients with solid organ versus hematologic neoplasms.
- Open Access
- 1 January 2023
- Published by SAGE Publications in Sage Open Medicine
- Vol. 11
Prevalence of cardiovascular risk factors in a historical cohort of people living with human immunodeficiency virus during a 10-year period
Objective: Data on the frequency of cardiovascular disease in people living with human immunodeficiency virus from low- and middle-income countries is scarce. Methods: We performed an observational study based on data from a historical cohort of people living with human immunodeficiency virus in Colombia during a 10-year follow-up to describe the prevalence of cardiovascular risk factors and their behavior according to CD4 count. Results: One thousand patients were initially included, out of which 390 had a 10-year follow-up. The mean age was 34 (standard deviation 10) years, and 90% were male. We observed an increase in the prevalence of dyslipidemia (29%–52%, p < 0.001) and obesity (1.1%–3.5%, p < 0.001). Major cardiovascular events occurred in less than 1% of patients. Patients with a CD4 count 3 had a higher frequency of acute myocardial infarction and obesity. Conclusion: Over time, people living with human immunodeficiency virus present with an increasing prevalence of cardiovascular risk factors, particularly those with a lower CD4 count.
- 1 January 2023
- Published by SAGE Publications in Sage Open Medicine
- Vol. 11
Open AccessPrevalence of cardiovascular risk factors in a historical cohort of people living with human immunodeficiency virus during a 10-year period
Objective: Data on the frequency of cardiovascular disease in people living with human immunodeficiency virus from low- and middle-income countries is scarce. Methods: We performed an observational study based on data from a historical cohort of people living with human immunodeficiency virus in Colombia during a 10-year follow-up to describe the prevalence of cardiovascular risk factors and their behavior according to CD4 count. Results: One thousand patients were initially included, out of which 390 had a 10-year follow-up. The mean age was 34 (standard deviation 10) years, and 90% were male. We observed an increase in the prevalence of dyslipidemia (29%–52%, p < 0.001) and obesity (1.1%–3.5%, p < 0.001). Major cardiovascular events occurred in less than 1% of patients. Patients with a CD4 count 3 had a higher frequency of acute myocardial infarction and obesity. Conclusion: Over time, people living with human immunodeficiency virus present with an increasing prevalence of cardiovascular risk factors, particularly those with a lower CD4 count.
- Open Access
- 3 October 2022
- Published by Universidad Nacional de Colombia in Revista de la Facultad de Medicina
- Vol. 71 (4) , e105619
Hipervitaminemia B12 y mortalidad en pacientes hospitalizados en un hospital universitario en Colombia
Introducción: Se ha reportado una asociación entre los niveles altos de vitamina B12 y la ocurrencia de múltiples enfermedades. Objetivo: describir las características clínicas de pacientes hospitalizados con hipervitaminemia B12, así como la tasa de mortalidad a un año. Materiales y métodos: estudio observacional retrospectivo realizado en 93 pacientes con hipervitaminemia B12 atendidos en el Hospital Universitario San Ignacio, en Bogotá Colombia entre 2013 y 2020. Los datos se describen utilizando medidas de tendencia central y de dispersión. Se realizaron análisis bivariados (prueba t de dos colas no pareada, prueba de chi-cuadrado o prueba U de Mann-Whitney según el tipo de variable) para determinar diferencias entre los pacientes con niveles altos de B12 y aquellos con niveles muy altos. Resultados: La mediana de edad fue 68 años y el 62.36% de los pacientes eran hombres. El 41.93% de los participantes tenía dos o más comorbilidades asociadas con la hipervitaminemia B12. Además, en 86.02% el nivel de vitamina B12 no fue interpretado como anormal por el médico tratante. Se encontraron diferencias significativas en el antecedente de tabaquismo (p = 0.043) y la presencia de lupus eritematoso sistémico (p = 0.012) entre los pacientes con niveles de B12 altos y aquellos con niveles muy altos. Finalmente, la tasa de mortalidad a 1 año fue de 59.13%. Conclusión: la tasa de mortalidad a un año fue alta y un elevado porcentaje de pacientes tenía al menos dos comorbilidades asociadas a la hipervitaminemia B12. Además, en la mayoría de los participantes, el médico tratante no interpretó correctamente el nivel elevado de esta vitamina. Introduction: An association between high B12 levels and the occurrence of multiple diseases has been reported. Objective: To describe the clinical characteristics of inpatients with B12 hypervitaminosis, as well as their 1-year mortality rate. Materials and methods: Retrospective observational study conducted in 93 patients with elevated B12 levels treated at the Hospital Universitario San Ignacio, in Bogotá (Colombia) between 2013 and 2020. Data are described using measures of central tendency and measures of dispersion. Bivariate analyses were performed (unpaired two-samples t-test, chi-square test or Mann-Whitney U test depending on the type of variable) to determine differences between patients with high B12 levels and those with very high levels. Results: Participant’s median age was 68 years, 62.36% were male and 41.93% had two or more B12 hypervitaminosis related comorbidities. In addition, in 86.02% of the patients, vitamin B12 level was not interpreted as abnormal by the treating physician. Significant differences were found between patients with high B12 levels and those with very high levels in terms of history of smoking (p= 0.043) and the presence of systemic lupus erythematosus (p= 0.012). Finally, the 1-year mortality rate was 59.13%. Conclusion: the 1-year mortality rate was high and a high percentage of patients had at least two comorbidities that were associated with high B12 levels. In addition, in most of the participants, the treating physician did not correctly interpret the elevated level of this vitamin.
- 3 October 2022
- Published by Universidad Nacional de Colombia in Revista de la Facultad de Medicina
- Vol. 71 (4) , e105619
Open AccessHipervitaminemia B12 y mortalidad en pacientes hospitalizados en un hospital universitario en Colombia
Introducción: Se ha reportado una asociación entre los niveles altos de vitamina B12 y la ocurrencia de múltiples enfermedades. Objetivo: describir las características clínicas de pacientes hospitalizados con hipervitaminemia B12, así como la tasa de mortalidad a un año. Materiales y métodos: estudio observacional retrospectivo realizado en 93 pacientes con hipervitaminemia B12 atendidos en el Hospital Universitario San Ignacio, en Bogotá Colombia entre 2013 y 2020. Los datos se describen utilizando medidas de tendencia central y de dispersión. Se realizaron análisis bivariados (prueba t de dos colas no pareada, prueba de chi-cuadrado o prueba U de Mann-Whitney según el tipo de variable) para determinar diferencias entre los pacientes con niveles altos de B12 y aquellos con niveles muy altos. Resultados: La mediana de edad fue 68 años y el 62.36% de los pacientes eran hombres. El 41.93% de los participantes tenía dos o más comorbilidades asociadas con la hipervitaminemia B12. Además, en 86.02% el nivel de vitamina B12 no fue interpretado como anormal por el médico tratante. Se encontraron diferencias significativas en el antecedente de tabaquismo (p = 0.043) y la presencia de lupus eritematoso sistémico (p = 0.012) entre los pacientes con niveles de B12 altos y aquellos con niveles muy altos. Finalmente, la tasa de mortalidad a 1 año fue de 59.13%. Conclusión: la tasa de mortalidad a un año fue alta y un elevado porcentaje de pacientes tenía al menos dos comorbilidades asociadas a la hipervitaminemia B12. Además, en la mayoría de los participantes, el médico tratante no interpretó correctamente el nivel elevado de esta vitamina. Introduction: An association between high B12 levels and the occurrence of multiple diseases has been reported. Objective: To describe the clinical characteristics of inpatients with B12 hypervitaminosis, as well as their 1-year mortality rate. Materials and methods: Retrospective observational study conducted in 93 patients with elevated B12 levels treated at the Hospital Universitario San Ignacio, in Bogotá (Colombia) between 2013 and 2020. Data are described using measures of central tendency and measures of dispersion. Bivariate analyses were performed (unpaired two-samples t-test, chi-square test or Mann-Whitney U test depending on the type of variable) to determine differences between patients with high B12 levels and those with very high levels. Results: Participant’s median age was 68 years, 62.36% were male and 41.93% had two or more B12 hypervitaminosis related comorbidities. In addition, in 86.02% of the patients, vitamin B12 level was not interpreted as abnormal by the treating physician. Significant differences were found between patients with high B12 levels and those with very high levels in terms of history of smoking (p= 0.043) and the presence of systemic lupus erythematosus (p= 0.012). Finally, the 1-year mortality rate was 59.13%. Conclusion: the 1-year mortality rate was high and a high percentage of patients had at least two comorbidities that were associated with high B12 levels. In addition, in most of the participants, the treating physician did not correctly interpret the elevated level of this vitamin.